.svg){kind=small}
Phase I trials have evolvedEU Legislative developments have redefined the boundaries of Phase I and opened a new era of opportunity to expedite compounds through the Early Phases. Pharmacology and patient studies can now be integrated or work independently of one another. Clinical & therapeutic innovations now enable Early Phase research to deliver more dynamic and insightful studies, maximizing the probability of a compound reaching the later Phases. We have put together the definitive one-day seminar to explore the new boundaries of Phase I.Click here for more information
-min.jpg)
.jpg)
Latest news
Richmond Pharmacology appoints Sandra Johnson as Director of Commercial Project Management
September 19, 2022
We are delighted to announce that Sandra Johnson will join Richmond Pharmacology as its new Director for Commercial Project Management
Read moreHow telemonitoring can revolutionise the way we treat patients – Tom York
November 17, 2022
Richmond Pharmacology always searches for the most innovative processes to improve clinical trials and the patients’ experiences and treatments.
Read moreEvents
JPW2022 (Japan Basic and Clinical Pharmacology Week 2022)
30 November – 3 December 2022
This event will be the 96th Annual Meeting of the Japanese Pharmacological Society and the 43rd Annual Meeting of the Japanese Society of Clinical Pharmacology.
View event
